VNRX VOLITIONRX LTD
In Vitro & In Vivo Diagnostic Substances · NYSE · SEC CIK 93314 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY134.0%
TTM net income YoY-3.8%
TTM EPS YoY62.7%
Revenue 3-yr CAGR74.3%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-512.6%
Net margin-698.5%
FCF margin-597.6%
EBITDA margin-489.2%
Returns
ROE—
ROA-352.5%
ROIC (approx.)—
Asset turnover0.50x
Leverage & solvency
Liabilities / assets481.7%
Debt / equity—
Current ratio0.33x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.85x
Accruals ratio-51.9%
Payout ratio—
Capex / revenue2.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.61M | $398,657 | $985,076 | $447,034 | $627,277 | $406,688 | $246,385 | $191,657 |
| R&D expense | $1.99M | $1.80M | $2.85M | $2.47M | $2.29M | $2.72M | $2.61M | $2.59M |
| SG&A expense | $2.38M | $2.21M | $2.63M | $1.80M | $2.48M | $2.94M | $2.24M | $2.13M |
| Operating income | -$3.33M | -$4.16M | -$5.35M | -$4.82M | -$5.10M | -$6.30M | -$5.52M | -$5.78M |
| Interest expense | $142,816 | $740,388 | $125,842 | — | $143,800 | $123,356 | $96,669 | — |
| Net income | -$3.80M | -$7.33M | -$6.66M | -$6.27M | -$5.38M | -$6.28M | -$5.42M | -$6.08M |
| EBITDA | -$3.16M | -$3.97M | -$5.14M | -$4.59M | -$4.85M | -$6.05M | -$5.27M | -$5.49M |
| EPS (diluted) | -0.21 | -0.85 | -0.97 | — | -0.99 | -1.22 | -1.12 | — |
| Weighted avg. shares (diluted) | 18.90M | 9.15M | 6.88M | — | 5.41M | 5.13M | 4.83M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $2.40M | $2.80M | $3.10M | $1.12M | $199,407 | $2.26M | $2.60M | $3.26M |
| Receivables | $182,629 | $277,355 | $252,242 | $317,808 | $309,085 | $189,597 | $187,830 | $110,574 |
| Current assets | $3.23M | $4.09M | $4.52M | $2.06M | $1.33M | $3.26M | $3.29M | $4.06M |
| PP&E, net | $3.41M | $3.56M | $3.77M | $4.03M | $4.24M | $4.50M | $4.35M | $4.43M |
| Intangibles | $297,052 | $305,133 | $318,901 | $316,704 | $301,033 | $306,377 | $317,129 | $313,747 |
| Total assets | $7.20M | $8.30M | $9.04M | $6.90M | $6.45M | $8.70M | $8.52M | $9.40M |
| Current liabilities | $9.89M | $13.49M | $13.57M | $12.23M | $11.42M | $9.24M | $8.27M | $7.79M |
| Short-term debt | $1.99M | $1.07M | $940,258 | $890,571 | $913,582 | $1.02M | $862,475 | $860,223 |
| Long-term debt | $4.72M | $5.98M | $6.35M | $5.82M | $5.57M | $5.77M | $5.53M | $3.95M |
| Total debt | $6.71M | $7.05M | $7.29M | $6.71M | $6.48M | $6.79M | $6.39M | $4.81M |
| Total liabilities | $34.70M | $41.84M | $42.40M | $42.49M | $42.40M | $41.80M | $37.55M | $35.51M |
| Shareholders' equity | -$26.12M | -$32.16M | -$31.97M | -$34.25M | -$34.64M | -$31.82M | -$27.77M | -$24.91M |
| Net debt | $4.31M | $4.25M | $4.19M | $5.59M | $6.28M | $4.53M | $3.79M | $1.55M |
| Shares outstanding | 32.81M | 12.04M | 7.93M | 6.29M | 109.62M | 103.98M | 100.75M | 96.10M |
| Cash flow statement | ||||||||
| Operating cash flow | -$4.59M | -$5.16M | -$5.28M | -$5.49M | -$3.63M | -$6.26M | -$4.30M | -$5.43M |
| Capital expenditure | $46,940 | $1,788 | $9,214 | $10,967 | $0 | $76,783 | $1,808 | $72,601 |
| Free cash flow | -$4.63M | -$5.16M | -$5.29M | -$5.50M | -$3.63M | -$6.34M | -$4.30M | -$5.50M |
| Investing cash flow | -$46,940 | -$1,788 | -$9,214 | -$10,967 | $0 | -$76,783 | -$1,808 | -$197,859 |
| Financing cash flow | $4.34M | $4.98M | $7.62M | $6.16M | $1.60M | $5.67M | $3.67M | $2.29M |
| Depreciation & amortization | $178,845 | $188,013 | $207,371 | $230,824 | $248,253 | $252,688 | $251,941 | $295,642 |
| Stock-based compensation | $186,948 | $238,004 | $224,981 | -$132,875 | $609,167 | $812,045 | $451,374 | $325,738 |
| Share buybacks | — | — | — | — | — | — | — | $0 |
Free plan shows the latest 8 periods; Pro shows all 63 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.